Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 11,392 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohorting Clear all

Conditions: Colorectal Cancer
Interventions: OSI-906, irinotecan; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Overdose
Interventions: administration of intravenous lipid emulsion; Other
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • Los Angeles, California

Conditions: Psoriasis
Interventions: PH-10 (0.002% Rose Bengal), PH-10 (0.005% Rose Bengal), PH-10 (0.01% Rose Bengal), Vehicle; Drug
Lead sponsor: Provectus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Oceanside, California • Miami, Florida • New York, New York + 1 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Paclitaxel poliglumex, Carboplatin, External beam radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 8
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more

Conditions: Substance Use Disorders, Behavioral Health, Addiction Psychological, Addiction Disorders, Meditation, Mindfulness Based Stress Reduction, Prevention
Interventions: Mindfulness and Meditation-Based Relapse Prevention Program; Behavioral
Lead sponsor: Bout Me Healing; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Follicular Lymphoma
Interventions: Venetoclax, Bendamustine, Rituximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 17
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 12 more

Conditions: Gastrointestinal Stromal Tumor
Interventions: Sunitinib, Regorafenib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: Not listed
Lead sponsor: Kiadis Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Neurofibromatosis 1, Nerve Sheath Neoplasms
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 120 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 1,937 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Systemic Lupus Erythematosus, Widespread Pain, Fibromyalgia
Interventions: Milnacipran; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Symptomatic COVID-19 Infection Laboratory-Confirmed, Waldenstrom Macroglobulinemia
Interventions: Ibrutinib, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Uveitis, Cancer, Infection, Mortality, Immunosuppression
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 6,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 4
States / cities: Baltimore, Maryland • Bethesda, Maryland • Boston, Massachusetts + 1 more

Conditions: Arthritis, Juvenile
Interventions: Ustekinumab, Guselkumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York + 5 more

Conditions: Gastrointestinal Diseases
Interventions: Observational; Other
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Chronic-kidney Disease Stage 5D on Stable Hemodialysis
Interventions: Single VS-105/placebo to healthy, Multiple VS-105/placebo to healthy, Multiple VS-105/placebo to HD subjects; Drug
Lead sponsor: Vidasym, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Lakewood, Colorado

Conditions: Infections, Bacterial
Interventions: 500mg IV GSK1322322/placebo, 1000mg oral GSK1322322/placebo, 1000mg IV GSK1322322/placebo, 1500mg oral GSK1322322/placebo dose, 1500mg IV GSK1322322/placebo, 2000mg IV GSK1322322J/placebo, 3000mg IV GSK1322322J/placebo, 1000mg IV GSK1322322J/placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: COVID-19
Interventions: Respiratory supports; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 2,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Psoriatic Arthritis
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Conversion Disorder
Interventions: Standard of Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Castrate Resistent Prostate Cancer
Interventions: BPX-201 vaccine plus AP1903; Biological
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Birmingham, Alabama • Dallas, Texas

Conditions: Smoking
Interventions: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®); Biological
Lead sponsor: Nabi Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Wound, Foot, Diabetic Foot Ulcer (DFU), Venus Leg Ulcer
Interventions: Microlyte®, IP 1: Membrane Wrap - Hydro; Device
Lead sponsor: Capsicure, LLC; Network
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 7
States / cities: San Diego, California • Coral Gables, Florida • Miami, Florida + 3 more

Conditions: Locally Advanced or Metastatic Solid Tumor
Interventions: Rebastinib, Paclitaxel; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 10 more

Search by objective public record fields.

OSI-906 and Irinotecan in Patients With Advanced Cancer

Prospective Cohort Study of Intravenous Lipid Emulsion for Resuscitating Critically-ill Poisoned Patients

Randomized Study of PH-10 for Psoriasis

A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer

Mindfulness and Meditation-Based Relapse Prevention for Substance Use Disorders

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST

Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

Prostate Cancer Prospective Cohort

The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients

Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study

A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

An Observational Study of Patients With Chronic Gastrointestinal Disease

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Respiratory Supports and COVID-19 Mortality

DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA

Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders

Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer

Antibody and Safety Study of 6 Doses of NicVAX in Smokers

CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors